NasdaqCM - Delayed Quote USD

ReShape Lifesciences Inc. (RSLS)

0.1698 -0.0082 (-4.61%)
At close: April 26 at 4:00 PM EDT
0.1735 +0.00 (+2.18%)
After hours: April 26 at 6:39 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
8,678.0000
8,678.0000
11,240.0000
13,600.0000
11,299.0000
Cost of Revenue
3,130.0000
3,130.0000
4,438.0000
5,252.0000
5,037.0000
Gross Profit
5,548.0000
5,548.0000
6,802.0000
8,348.0000
6,262.0000
Operating Expense
20,187.0000
20,187.0000
33,880.0000
35,581.0000
18,719.0000
Operating Income
-14,639.0000
-14,639.0000
-27,078.0000
-27,233.0000
-12,457.0000
Net Non Operating Interest Income Expense
26.0000
26.0000
-113.0000
-832.0000
-2,049.0000
Other Income Expense
3,278.0000
3,278.0000
-19,403.0000
-35,355.0000
-7,305.0000
Pretax Income
-11,335.0000
-11,335.0000
-46,594.0000
-63,420.0000
-21,811.0000
Tax Provision
52.0000
52.0000
-380.0000
-274.0000
-181.0000
Net Income Common Stockholders
-11,387.0000
-11,387.0000
-46,214.0000
-63,146.0000
-21,630.0000
Diluted NI Available to Com Stockholders
-11,387.0000
-11,387.0000
-46,214.0000
-63,146.0000
-21,630.0000
Basic EPS
-38.56
-1.91
-108.90
-288.97
-277.00
Diluted EPS
-38.56
-1.91
-108.90
-288.97
-277.00
Basic Average Shares
2,229.3600
5,956.5490
424.3900
218.5220
78.0950
Diluted Average Shares
2,229.3600
5,956.5490
424.3900
218.5220
78.0950
Total Operating Income as Reported
-15,383.0000
-15,383.0000
-46,351.0000
-57,882.0000
-12,457.0000
Total Expenses
23,317.0000
23,317.0000
38,318.0000
40,833.0000
23,756.0000
Net Income from Continuing & Discontinued Operation
-11,387.0000
-11,387.0000
-46,214.0000
-63,146.0000
-21,630.0000
Normalized Income
-13,880.2400
-13,880.2400
-26,955.3120
-27,932.4200
-14,383.4400
Interest Expense
--
--
113.0000
832.0000
2,049.0000
Net Interest Income
26.0000
26.0000
-113.0000
-832.0000
-2,049.0000
EBIT
-14,639.0000
-14,639.0000
-27,078.0000
-62,588.0000
-19,762.0000
EBITDA
-14,485.0000
-14,485.0000
-24,925.0000
-60,617.0000
-18,095.0000
Reconciled Cost of Revenue
3,130.0000
3,130.0000
4,438.0000
5,252.0000
5,037.0000
Reconciled Depreciation
154.0000
154.0000
2,153.0000
1,971.0000
1,667.0000
Net Income from Continuing Operation Net Minority Interest
-11,387.0000
-11,387.0000
-46,214.0000
-63,146.0000
-21,630.0000
Total Unusual Items Excluding Goodwill
3,156.0000
3,156.0000
-19,414.0000
-35,355.0000
-7,305.0000
Total Unusual Items
3,156.0000
3,156.0000
-19,414.0000
-35,355.0000
-7,305.0000
Normalized EBITDA
-17,641.0000
-17,641.0000
-5,511.0000
-25,262.0000
-10,790.0000
Tax Rate for Calcs
0.0002
0.0002
0.0000
0.0000
0.0000
Tax Effect of Unusual Items
662.7600
662.7600
-155.3120
-141.4200
-58.4400
12/31/2020 - 10/6/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

HSCS Heart Test Laboratories, Inc.
0.0974
-2.50%
 
INBS Intelligent Bio Solutions Inc.
2.6900
+8.03%
 
IINN Inspira Technologies Oxy B.H.N. Ltd.
1.8900
-0.53%
 
SINT Sintx Technologies, Inc.
0.0404
+10.38%
 
BJDX Bluejay Diagnostics, Inc.
0.6419
+16.50%
 
NUWE Nuwellis, Inc.
0.1678
-41.94%
 
TIVC Tivic Health Systems, Inc.
1.0400
-3.70%
 
USAQ QHSLab, Inc.
0.0945
+5.00%
 
OPGN OpGen, Inc.
0.5149
-3.21%
 
AEMD Aethlon Medical, Inc.
1.3600
-10.82%